City Different Investments, an investment management firm, released Q2 2026 investor update for its global equity strategies. A copy of the letter can be downloaded here. City Different global equity strategies delivered strong results in the second quarter, but trailed the global market driven by AI enthusiasm. Its Focused Global returned +7.08%, and Global Equity returned +5.36% during the quarter. This compared to the MSCI All Country World Index return of +14.93%. YTD, the strategies returned +11.28% and +5.29%, vs +11.25% for the index. The global strategies involve focused portfolios of long-only equities selected on a global basis, aimed at long-term investment potential. The firm remains optimistic about these portfolios, which are constructed based on long-term fundamental ****** sments. In addition, please check the Fund's top five holdings to know its best picks in 2026.
In its Q2 2026 investor letter, City Different Investments highlighted ICON Public Limited Company (NASDAQ:ICLR). ICON Public Limited Company (NASDAQ:ICLR) is a clinical research organization that provides outsourced development and commercialization services to the pharmaceutical, biotechnology, and medical device industries. On July 21, 2026, ICON Public Limited Company (NASDAQ:ICLR) stock closed at $166.62 per share. One-month return of ICON Public Limited Company (NASDAQ:ICLR) was 4.54%, and its shares lost 1.51% over the past 52 weeks. ICON Public Limited Company (NASDAQ:ICLR) has a market capitalization of about $12.72 billion.
City Different Investments stated the following regarding ICON Public Limited Company (NASDAQ:ICLR) in its Q2 2026 investor update:
"ICON Public Limited Company (NASDAQ:ICLR) was a new purchase and became the top contributor to our results for the second quarter. Founded in 1990 by two Irish doctors, this Dublin-based provider of clinical research services and ****** ytics saw its stock price clobbered over the past two years due to the triple whammy of: 1/ a post-COVID-19 demand slowdown; 2/ AI-related fears; and 3/ an accounting error that led to a minor restatement of results. However, our team has followed this industry since 2019, and we bought ICON eagerly in April once the valuation became compelling. Now the accounting error has already been fixed, and leading growth indicators, such as bookings and cancellations, are encouraging. Our research suggests that ICON could be a net beneficiary of AI due to proprietary data, domain expertise, and regulatory barriers, among other factors. A combination of an improving growth rate and a declining share count could boost ICON's valuation from here."

#public #iclr

City Different Investments, an investment management firm, released Q2 2026 investor update for its global equity strategies. A copy of the letter can be downloaded here. City Different global equity strategies delivered strong results in the second quarter, but trailed the global market driven by AI enthusiasm. Its Focused Global returned +7.08%, and Global Equity returned +5.36% during the quarter. This compared to the MSCI All Country World Index return of +14.93%. YTD, the strategies returned +11.28% and +5.29%, vs +11.25% for the index. The global strategies involve focused portfolios of long-only equities selected on a global basis, aimed at long-term investment potential. The firm remains optimistic about these portfolios, which are constructed based on long-term fundamental **** sments. In addition, please check the Fund's top five holdings to know its best picks in 2026.
In its Q2 2026 investor letter, City Different Investments highlighted ICON Public Limited Company (NASDAQ:ICLR). ICON Public Limited Company (NASDAQ:ICLR) is a clinical research organization that provides outsourced development and commercialization services to the pharmaceutical, biotechnology, and medical device industries. On July 21, 2026, ICON Public Limited Company (NASDAQ:ICLR) stock closed at $166.62 per share. One-month return of ICON Public Limited Company (NASDAQ:ICLR) was 4.54%, and its shares lost 1.51% over the past 52 weeks. ICON Public Limited Company (NASDAQ:ICLR) has a market capitalization of about $12.72 billion.
City Different Investments stated the following regarding ICON Public Limited Company (NASDAQ:ICLR) in its Q2 2026 investor update:
"ICON Public Limited Company (NASDAQ:ICLR) was a new purchase and became the top contributor to our results for the second quarter. Founded in 1990 by two Irish doctors, this Dublin-based provider of clinical research services and **** ytics saw its stock price clobbered over the past two years due to the triple whammy of: 1/ a post-COVID-19 demand slowdown; 2/ AI-related fears; and 3/ an accounting error that led to a minor restatement of results. However, our team has followed this industry since 2019, and we bought ICON eagerly in April once the valuation became compelling. Now the accounting error has already been fixed, and leading growth indicators, such as bookings and cancellations, are encouraging. Our research suggests that ICON could be a net beneficiary of AI due to proprietary data, domain expertise, and regulatory barriers, among other factors. A combination of an improving growth rate and a declining share count could boost ICON's valuation from here."

#limited #company #global #city

Artisan Partners, an investment management firm, issued its first-quarter 2026 investor letter for the "Artisan Mid Cap Value Fund". A copy of this letter is available for download here. In Q1 2026, the portfolio underperformed the benchmark Russell Midcap Value Index as the market favored momentum-driven stocks over quality factors. Some holdings faced company-specific setbacks and negative sentiment. The Fund's Investor Class: ARTQX returned -4.93%, Advisor Class: APDQX declined by -4.90%, and Institutional Class: APHQX fell by -4.97%, all trailing the Index's 3.68% gain. The equity market in the quarter was mixed, with mid- and small-cap indices showing resilience despite lagging large-cap growth stocks. Volatility increased, initially fueled by interest in AI and private credit, but escalated after the outbreak of war in Iran, leading to rising oil prices. Sector performance varied, with energy leading the gains. The Fund continues to seek companies capable of value growth during market dislocations at attractive entry points. Also, review the Fund's top five holdings to see its best picks for 2026.
In its first-quarter 2026 investor letter, Artisan Mid Cap Value Fund highlighted ICON Public Limited Company (NASDAQ:ICLR). ICON Public Limited Company (NASDAQ:ICLR) is a clinical research organization that provides outsourced development and commercialization services to the pharmaceutical, biotechnology, and medical device industries. On July 7, 2026, ICON Public Limited Company (NASDAQ:ICLR) stock closed at $168.72 per share. One-month return of ICON Public Limited Company (NASDAQ:ICLR) was 16.69%, and its shares gained 12.08% over the past 52 weeks. ICON Public Limited Company (NASDAQ:ICLR) has a market capitalization of about $12.92 billion.
Artisan Mid Cap Value Fund stated the following regarding ICON Public Limited Company (NASDAQ:ICLR) in its Q1 2026 investor letter:
"Among the biggest decliners were ICON Public Limited Company (NASDAQ:ICLR), Humana, Gartner and Pinterest, each of which dropped by 30% or more during the quarter. ICON, a leading provider of outsourced clinical development services to pharmaceutical and biotechnology companies, was the largest detractor. The stock fell sharply—nearly 49% in a single day—after the company announced it would delay its financial results due to an internal review of its accounting, specifically related to revenue recognition in recent years. While ICON indicated its cash position remains intact, the situation raises uncertainty around reported earnings and has pressured investor confidence in the near term. This development comes at a challenging time for the broader contract research industry, where funding constraints and cautious spending by biotech and pharmaceutical companies have already weighed on demand. Although the lack of updated financials limits near term visibility, we believe the stock reflects a more attractive valuation based on conservative ****** umptions for free cash fl

Artisan Partners, an investment management firm, issued its first-quarter 2026 investor letter for the "Artisan Mid Cap Value Fund". A copy of this letter is available for download here. In Q1 2026, the portfolio underperformed the benchmark Russell Midcap Value Index as the market favored momentum-driven stocks over quality factors. Some holdings faced company-specific setbacks and negative sentiment. The Fund's Investor Class: ARTQX returned -4.93%, Advisor Class: APDQX declined by -4.90%, and Institutional Class: APHQX fell by -4.97%, all trailing the Index's 3.68% gain. The equity market in the quarter was mixed, with mid- and small-cap indices showing resilience despite lagging large-cap growth stocks. Volatility increased, initially fueled by interest in AI and private credit, but escalated after the outbreak of war in Iran, leading to rising oil prices. Sector performance varied, with energy leading the gains. The Fund continues to seek companies capable of value growth during market dislocations at attractive entry points. Also, review the Fund's top five holdings to see its best picks for 2026.
In its first-quarter 2026 investor letter, Artisan Mid Cap Value Fund highlighted ICON Public Limited Company (NASDAQ:ICLR). ICON Public Limited Company (NASDAQ:ICLR) is a clinical research organization that provides outsourced development and commercialization services to the pharmaceutical, biotechnology, and medical device industries. On July 7, 2026, ICON Public Limited Company (NASDAQ:ICLR) stock closed at $168.72 per share. One-month return of ICON Public Limited Company (NASDAQ:ICLR) was 16.69%, and its shares gained 12.08% over the past 52 weeks. ICON Public Limited Company (NASDAQ:ICLR) has a market capitalization of about $12.92 billion.
Artisan Mid Cap Value Fund stated the following regarding ICON Public Limited Company (NASDAQ:ICLR) in its Q1 2026 investor letter:
"Among the biggest decliners were ICON Public Limited Company (NASDAQ:ICLR), Humana, Gartner and Pinterest, each of which dropped by 30% or more during the quarter. ICON, a leading provider of outsourced clinical development services to pharmaceutical and biotechnology companies, was the largest detractor. The stock fell sharply—nearly 49% in a single day—after the company announced it would delay its financial results due to an internal review of its accounting, specifically related to revenue recognition in recent years. While ICON indicated its cash position remains intact, the situation raises uncertainty around reported earnings and has pressured investor confidence in the near term. This development comes at a challenging time for the broader contract research industry, where funding constraints and cautious spending by biotech and pharmaceutical companies have already weighed on demand. Although the lack of updated financials limits near term visibility, we believe the stock reflects a more attractive valuation based on conservative ******* umptions for free cash f

The healthcare sector, stuffed as it is with biotechs concocting new medicines and pharmaceutical companies making billions by selling them, has several segments that often go overlooked. One of these is the clinical research organization (CRO) ******* e.
But investors certainly had their eyes on it on Wednesday, as one segment company did very well in its first quarter of this year. Icon (NASDAQ: ICLR) delivered the goods for its shareholders with an estimates-topping performance in the period. It was rewarded by Mr. Market with a nearly 11% gain its share price that trading session.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
In the quarter, Icon booked total revenue of just over $2 billion, which was incrementally (by 0.9%) higher than the same period of 2025. The company's net income not under generally accepted accounting principles (GAAP) went in the opposite direction, falling by 27% to just under $193 million ($2.50 per share).
Despite the bottom-line slide, Icon beat ******* yst estimates for that metric. Prognosticators tracking the specialty healthcare stock were modeling $2 billion in revenue, but $2.43 per share for non-GAAP (adjusted) net income.

Greenskeeper **** et Management, an independent firm that specializes in disciplined value investing, recently released its Q1 2026 scorecard. A copy is available to download here. The Middle East conflict triggered a sharp stock sell-off in the market, resulting in the Greenskeeper Value Fund posting a -8.1% return in Q1. Despite this challenging quarter, the fund took the opportunity to reinforce its portfolio. Please review the Fund's top five holdings to gain insights into their key selections for 2026.
In its first-quarter 2026 investor letter, Greenskeeper **** et Management highlighted stocks like ICON Public Limited Company (NASDAQ:ICLR). ICON Public Limited Company (NASDAQ:ICLR) is a clinical research organization that provides outsourced development and commercialization services to the pharmaceutical, biotechnology, and medical device industries. On June 12, 2026, ICON Public Limited Company (NASDAQ:ICLR) stock closed at $146.18 per share. One-month return of ICON Public Limited Company (NASDAQ:ICLR) was 28.48%, and its shares lost 0.58% over the past 52 weeks. ICON Public Limited Company (NASDAQ:ICLR) has a market capitalization of about $11.19 billion.
Greenskeeper **** et Management stated the following regarding ICON Public Limited Company (NASDAQ:ICLR) in its Q1 2026 investor letter:
"ICON Public Limited Company (NASDAQ:ICLR) -39.3% was our primary detractor this quarter following the February announcement of an internal Audit Committee investigation into revenue recognition practices from 2023 through 2025. While the market's reaction was severe, we believe it was an overreaction. Management anticipates the revenue restatement will be less than 2% for each affected year. While disappointing, we believe this issue was an internal matter and will not have any material long-term impact on ICLR's ability to serve its customers. It is also unlikely to have a material impact on the company's $1 billion of free cash flow. We used the selloff as an opportunity to increase our position, and the stock has already begun to rebound. As the pharmaceutical environment continues to improve, we remain confident that the company will capture its fair share of clinical trial activity. With the stock trading at roughly 10x trailing earnings, we believe that the shares remain materially undervalued."
ICON Public Limited Company (NASDAQ:ICLR) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 49 hedge fund portfolios held ICON Public Limited Company (NASDAQ:ICLR) at the end of the first quarter, up from 41 in the previous quarter. While we acknowledge the potential of ICON Public Limited Company (NASDAQ:ICLR) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best